Though both liraglutide and empagliflozin reduce blood pressure, a risk factor to HF, the difference in HF hospitalization cannot be accounted for even when blood pressure is pre-controlled, and Scheen et al
Products referenced are intended for laboratory research use only and are not for human consumption
Clinical trials and real-world data show that NSAIDs increase the risk of nausea, vomiting, and abdominal pain in patients already experiencing semaglutide-related GI effects
Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, Das S, Lee CJ, Glass LC, Senyucel C, Dunn JP, SURMOUNT-5 Trial Investigators (2025) Tirzepatide as compared with semaglutide for the treatment of obesity
Strengthening the immune system